ArticlePLoS neglected tropical diseases2025
Target product profiles for new diagnostics to inform strongyloidiasis control programs.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of the diagnostic performance of a commercial ELISA based on two recombinant antigens for the diagnosis of Strongyloides stercoralis infection.Parasites & vectors · 2026Article
- An Agar-Free, Glass Bead-Based Method for the Culture ofDiagnostics (Basel, Switzerland) · 2026Article
- Article
- Integration of diagnostics for Strongyloides stercoralis into the soil-transmitted helminths control programme in Rwanda.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe World Health Organization calls for the development of new diagnostics to support large-scale deworming programs against strongyloidiasis. To better steer research and development (R&D) of new diagnostics, it is imperative to identify the minimal requirements that new diagnostics should meet, the so-called target product profiles (TPPs). While diagnostic TPPs exist for other major soil-transmitted helminthiases, none exist for strongyloidiasis.
methodsWe investigated a range of potential diagnostic TPPs using our previously developed simulation framework for the effect of imperfect diagnostics on the cost and correctness of program decisions. With this framework, we studied the minimum requirements for diagnostic performance, cost per test and sample throughput for future assays while comparing the survey costs with those of the reference Baermann method. As potential assay platforms, we considered antibody (Ab)-detecting assays, including a point-of-care lateral flow assay (LFA) and a laboratory-based Ab-ELISA. We also determined cost-efficient school-based survey designs for two currently available assays: Bordier Ab-ELISA and a prototype NIE-LFA. PRINCIPAL
findingsOur findings highlighted that (i) specificity rather than sensitivity is a critical parameter to consider for R&D of new diagnostic methods for monitoring control programs; (ii) the requirements for diagnostic performance became less stringent with an increasing sample size and when higher risks of incorrect decision-making were accepted. When focusing on the assay formats, the LFA resulted in lower survey costs compared to the Baermann method. Ab-ELISA was cost-efficient only if the diagnostic performance was nearly perfect combined with low cost per test and high sample throughput. Of all the three assays considered here, the prototype NIE-LFA allowed for the most cost-efficient survey designs. CONCLUSION/SIGNIFICANCE: R&D should focus on developing point-of-care assays with high specificity. The prototype NIE-LFA is a cost-efficient alternative to Baermann to support control programs for strongyloidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.